Literature DB >> 8875347

Pulmonary distribution of alfentanil and sufentanil studied with system dynamics analysis.

F Boer1, A Hoeft, M Scholz, J G Bovill, A G Burm, A Hak.   

Abstract

We applied a system dynamics approach to the study of the pulmonary distribution of alfentanil and sufentanil in anesthetized pigs and patients, respectively. This method allows estimation of the mean transit time through the lungs and calculation of the volume of distribution of alfentanil in the lungs. In the first part of the study the pulmonary distribution of alfentanil was studied in six anesthetized pigs during three hemodynamic states (control, partial clamping of the inferior vena cave, and complete clamping of the right pulmonary artery). In the second part of the study the pulmonary distribution of sufentanil was studied in 10 patients, scheduled for elective CABG, during and after a constant rate infusion of 10 min. Pulmonary passage of the opioids was characterized by functions of transit times, derived from the pulmonary arterial and systemic arterial concentration curves. Pulmonary distribution volumes were calculated from the mean transit time and pulmonary blood flow. Pulmonary distribution volume of alfentanil during the control measurement was significantly higher (486 +/- 88 ml) than during either partial caval clamping (346 +/- 89 ml, p < 0.05) or right pulmonary artery clamping (336 +/- 56 ml, p < 0.05). There was no change in the extravascular volume of distribution of alfentanil with each hemodynamic state. Pulmonary volume of distribution of sufentanil in the patients was 22.6 (10.9) L. Pulmonary distribution of opioids can be studied using system dynamics analysis, both after bolus injection and during and after infusion. This method can be used for periods beyond the initial passage of the drug through the lungs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875347     DOI: 10.1007/bf02353489

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  28 in total

1.  Validity of the lagged normal density function as a model for pulmonary indicator dispersion.

Authors:  J C Böck; A Hoeft; G Hellige
Journal:  Biomed Instrum Technol       Date:  1990 Jan-Feb

Review 2.  Clinical relevance of lung water measurement with the thermal-dye dilution technique.

Authors:  J C Böck; F R Lewis
Journal:  J Surg Res       Date:  1990-03       Impact factor: 2.192

3.  Absence of morphine glucuronidation in the human lung.

Authors:  F M Ratcliffe
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of alterations in pulmonary blood flow on lung-exchangeable water in the dog.

Authors:  B W Kirk
Journal:  J Appl Physiol       Date:  1969-11       Impact factor: 3.531

5.  In vivo lung uptake of lidocaine in pigs.

Authors:  A Bertler; D H Lewis; J B Löfström; C Post
Journal:  Acta Anaesthesiol Scand       Date:  1978       Impact factor: 2.105

6.  Absence of metabolism of morphine during accumulation by isolated perfused rabbit lung.

Authors:  M E Davis; H M Mehendale
Journal:  Drug Metab Dispos       Date:  1979 Nov-Dec       Impact factor: 3.922

7.  Flow dependence of norepinephrine extraction by isolated perfused rat lungs.

Authors:  R A Roth
Journal:  Am J Physiol       Date:  1982-05

8.  The elimination of bupivacaine (Marcain) after short intravenous infusion in the dog: with special reference to the role played by the liver and lungs.

Authors:  L Irestedt; M Andreen; P Belfrage; T Fagerström
Journal:  Acta Anaesthesiol Scand       Date:  1978       Impact factor: 2.105

9.  Uptake of sufentanil, alfentanil and morphine in the lungs of patients about to undergo coronary artery surgery.

Authors:  F Boer; J G Bovill; A G Burm; R A Mooren
Journal:  Br J Anaesth       Date:  1992-04       Impact factor: 9.166

10.  Pulmonary extraction of [3H]bupivacaine: modification by dose, propranolol and interaction with [14C]5-hydroxytryptamine.

Authors:  P Rothstein; J S Cole; B R Pitt
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.